These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32170593)

  • 21. Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients.
    Palanisamy AP; Al Manasra AR; Pilch NA; Dowden JE; Nadig SN; McGillicuddy JW; Baliga PK; Chavin KD; Taber DJ
    Clin Transplant; 2015 Mar; 29(3):222-6. PubMed ID: 25557762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM; Keating GM
    Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of immunosuppression induction with basiliximab compared to antithymocyte-globulin in adult heart transplant patients.
    Eberhardt TE; Kim DH; Nethersole S; Pearson GJ
    Clin Transplant; 2024 Jun; 38(6):e15332. PubMed ID: 38804609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Significant Increase in Cytomegalovirus (CMV) Infection in Solid Organ Transplants Associated With Increased Use of Thymoglobulin as Induction Therapy?
    Romao EA; Yamamoto AY; Gaspar GG; Garcia TMP; Muglia VA; Nardin MEP; Molina CAF; de Figueiredo VCTP; Moyses-Neto M
    Transplant Proc; 2023 Nov; 55(9):2035-2040. PubMed ID: 37778934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes after anti-thymocyte globulin vs Basiliximab induction before deceased donor kidney transplants.
    Hafeez MS; Haq MU; Bakhthiyar SS; Azhar K; Awan AAY; Ramana Murthy BV; Abbas R
    Transpl Immunol; 2022 Dec; 75():101733. PubMed ID: 36347493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Induction Therapy in Kidney Transplantation: A Network Meta-Analysis.
    Hwang SD; Lee JH; Lee SW; Park KM; Kim JK; Kim MJ; Song JH
    Transplant Proc; 2018 May; 50(4):987-992. PubMed ID: 29731098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression.
    Sonmez O; Ozcan SG; Karaca C; Atli Z; Dincer MT; Trabulus S; Seyahi N
    Exp Clin Transplant; 2024 Apr; 22(4):270-276. PubMed ID: 38742317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up.
    Mangus RS; Fridell JA; Vianna RM; Kwo PY; Chen J; Tector AJ
    Liver Transpl; 2012 Jul; 18(7):786-95. PubMed ID: 22237953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data.
    Cai J; Terasaki PI
    Transplantation; 2010 Dec; 90(12):1511-5. PubMed ID: 21057388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database.
    Jindal RM; Das NP; Neff RT; Hurst FP; Falta EM; Elster EA; Abbott KC
    Am J Nephrol; 2009; 29(6):501-8. PubMed ID: 19060477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
    Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
    Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-2 receptor antagonist therapy leads to increased tacrolimus levels after kidney transplantation.
    Lin S; Henning AK; Akhlaghi F; Reisfield R; Vergara-Silva A; First MR
    Ther Drug Monit; 2015 Apr; 37(2):206-13. PubMed ID: 25162212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
    Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of rabbit anti-thymocyte globulin vs basiliximab induction in pediatric liver transplant recipients.
    Newland DM; Royston MJ; McDonald DR; Nemeth TL; Wallace-Boughter K; Carlin K; Horslen S
    Pediatr Transplant; 2019 Dec; 23(8):e13573. PubMed ID: 31512802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
    Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D
    Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
    Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
    Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.